FOLD Stock Analysis: Buy, Sell, or Hold?
FOLD - Amicus Therapeutics, Inc
$14.33
0.00 (0.00%)
▲
5d:
+0.0%
30d:
+0.35%
90d:
+47.28%
BUY
MODERATE Confidence
Analysis Updated: Mar 5, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When FOLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: FOLD shows positive signals but monitor for confirmation. Market pricing in 7.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: FOLD shows positive signals but monitor for confirmation. Market pricing in 7.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$35.05
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$21.76
34.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FOLD is currently trading at $14.33, which is considered slightly high relative to its 30-day fair value range of $14.29 to $14.35. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.6) compared to its historical average (19.6). Remarkably, the market is currently pricing in an annual earnings decline of 7.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, FOLD is in a strong uptrend. The price is currently testing key support at $14.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, FOLD is in a strong uptrend. The price is currently testing key support at $14.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$14.29 -
$14.35
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($14.50)
Fair Price Analysis
30-Day Fair Range
$14.29 -
$14.35
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$14.31
Resistance Level
$14.37
Current Trend
Strong Uptrend
Technical data as of
Mar 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.61
Wall Street Target
$14.50
(+1.2%)
Revenue Growth (YoY)
23.7%
Earnings Growth (YoY)
-95.5%
Profit Margin
-4.3%
Valuation Discount vs History
-7.4% cheaper
PE vs Historical
15.6 vs 19.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.4%
(market-implied from PE analysis)
1-Year Target
$13.27
(-7%)
2-Year Target
$12.29
(-14%)
3-Year Target
$11.38
(-21%)
3-Yr Target (if PE normalizes)
(PE: 16→20)
$14.29
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.6, Growth: 42.0%)
$59.37
(+314%)
Base:
(SPY PE: 15.6, Growth: 42.0%)
$41.02
(+186%)
Bear:
(PE: 13.3, Growth: 42.0%)
$34.86
(+143%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.6 to 19.6
Stabilization Target:
$18.00
(+25.6%)
PE Expansion Potential:
+25.6%
Share & Embed Analysis
Last updated: March 06, 2026 5:26 AM ET
Data refreshes hourly during market hours. Next update: 6:26 AM
Data refreshes hourly during market hours. Next update: 6:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FOLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Bradley L Campbell
SELL
75000 shares
2026-01-20
David Michael Clark
SELL
25642 shares
2025-12-19
Bradley L Campbell
SELL
77926 shares
2025-12-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 61 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$409 | 60 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$34 | 53 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$40 | 64 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$41 | 56 HOLD |
Advanced FOLD Option Strategies
Professional options setups generated by AI based on today's FOLD price and gamma walls.
